Get the Stockscreener App
11.69
2.01%
-0.24
Delcath Systems Inc stock is traded at $11.69, with a volume of 582.70K.
It is down -2.01% in the last 24 hours and up +5.41% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$11.93
Open:
$12.09
24h Volume:
582.70K
Relative Volume:
1.39
Market Cap:
$403.56M
Revenue:
$90.44M
Net Income/Loss:
$561.00K
P/E Ratio:
1,948.33
EPS:
0.006
Net Cash Flow:
$19.19M
1W Performance:
-0.64%
1M Performance:
+5.41%
6M Performance:
+17.72%
1Y Performance:
-17.44%
1-Day Range:
$11.64
$12.18
1-Week Range:
$11.51
$12.21
52-Week Range:
$8.12
$14.48
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.69 | 403.56M | 90.44M | 561.00K | 19.19M | 0.006 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Delcath Systems Inc (DCTH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Delcath Systems Inc (DCTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Delcath Systems Inc (DCTH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Delcath Systems Inc (DCTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Delcath Systems Inc (DCTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Delcath Systems Inc (DCTH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Delcath Systems Inc (DCTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Delcath Systems, Inc. - MLQ.ai
Delcath Systems, Inc. Stock 12‑Month Price Target Cut to $20.83, Implies 95% Upside - TradingView
European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan
Delcath therapy included in European uveal melanoma guidelines - Investing.com
FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC - Quantisnow
(DCTH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Abbott’s $21bn Bet on Exact Sciences Takes Center Stage at ASCO 2026 - Citeline News & Insights
Delcath Systems Q1 2026 Earnings: Narrowed Loss Surprises, Stock AdvancesCore Business Growth - newsline.com
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - BioSpace
Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Moomoo
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Bolstered by Cost DisciplineMargin Expansion Trends - newsline.com
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued - GuruFocus
Delcath Systems announces inducement grants - Medical Buyer
How (DCTH) Movements Inform Risk Allocation Models - Stock Traders Daily
Implied volatility surging for Delcath Systems stock options - MSN
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Tribune News
Delcath Systems announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Delcath hires receive 24,500 stock units over 3 years - Stock Titan
Dental EconomicsDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Delcath Systems (DCTH) director receives grant of 22,500 stock options at $11.61 - Stock Titan
Delcath Systems (NASDAQ: DCTH) director receives 22,500 stock options at $11.61 strike - Stock Titan
Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61 - Stock Titan
Director at Delcath (NASDAQ: DCTH) awarded 22,500 stock options - Stock Titan
Delcath (DCTH) awards director 22,500 options at $11.61 strike - Stock Titan
Delcath Systems, Inc. 8-K Filing May 13, 2026 – Company Information, Equity Incentive Plan, and SEC Compliance 212 - Minichart
Delcath Shareholders Approve Expanded Equity Plan and Governance - TipRanks
Delcath Systems shareholders approve equity plan amendment and board elections - Investing.com Nigeria
Delcath Systems shareholders approve equity plan amendment and board elections By Investing.com - Investing.com South Africa
Delcath (NASDAQ: DCTH) approves 1.8M-share boost to 2020 equity plan - Stock Titan
Earnings call transcript: Delcath Systems Q1 2026 beats EPS forecast, stock rises - Investing.com Nigeria
Liver cancer-focused Delcath heads to Nasdaq BioConnect investor conference May 19 - Stock Titan
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference - Yahoo Finance
TradingKey - TradingKey
Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep Dive - AlphaStreet
Tangible book value per share of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems Balances Growth with Rising Costs - The Globe and Mail
MSN Money - MSN
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Delcath Systems, Inc. (NASDAQ:DCTH) Q1 2026 Earnings Call Transcript - Insider Monkey
Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results - MarketBeat
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):